



Speakers



Dr Ulli Backofen Boehringer Ingelheim, Germany



Dr Heiko Brunner Hamburg, Germany



Dr Thomas Fürst Boehringer Ingelheim, Germany



Dr Josef Hofer EXDRA, Germany



Dr Cornelia Nopitsch-Mai Formerly Quality Assessor, Germany



Dr Thomas Uhlich Bayer, Germany

Stability Testing for Drug Substances and Drug Products

Live Online Training on 12/13 November 2025



Highlights

- Stability Testing from Early Development to Product Launch
- Guidelines for Stability Testing
- Stability Testing for
 - Biologicals
 - **Drug Substances**
 - **Drug Products**
- Submitting Stability Data
- Evaluation of Stability Results Statistical Considerations

Programme

Objective

This Live Online Training is intended to provide information on different aspects of stability testing. The course will be opened by an overview of stability testing with a special focus on the ICH Guidelines. In the subsequent presentations, important aspects of stability testing for biologicals and throughout drug development are discussed. Another lecture focuses on stability testing for Drug Substances, followed by a talk on Drug Products. In a further presentation, the focus lies on to the various aspects of submitting stability data. Finally, statistical considerations will be covered in another lecture.

Background

Analytical methods that were not "stability-indicating" are frequently cited in FDA 483s and Warning Letters. This conference will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results.

The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.

Finally, specifications for the API (drug substance), excipient(s) and the drug product are part of the quality section of the marketing authorisation application which has to be submitted to the competent authority.

Target Audience

This Live Online Training is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities. Participants have the opportunity to exchange their experiences they gained with the different aspects of 'specifications' with the experts from the API and pharmaceutical industry as well as with members of competent authorities.

Programme

Current ICH and CHMP Guidelines for Stability Testing

- Overview of Stability Guidelines
- Concepts of Stability Testing
- Retest period and shelf-life
- Post-marketing Stability Studies
- Future Activities

Stability Testing for Biologicals

- Overview of regulatory requirements
- Types of stability studies for Biopharmaceuticals
- Practical aspects of stability studies with Biopharmaceuticals
- Degradation pathways
- Setting shelf life during early and late stage development

Stability Testing throughout Drug Development

- Must the development stability programme meet ICH Q1A?
- Stability testing from early development to product launch
- Clinical stability for comparators
- Site specific stability

Stability Testing for Drug Substances

- Stability protocols
- Stress testing
- Photostability testing
- Documentation

Stability Testing for Drug Products

- Strategy of Stability Testing
- Performance of new Drug Products
- Related Finished Products with existing substances
- Follow-up Stability Testing

Submitting Stability Data

- Regulatory Strategy Stability
- Drug Substance and Drug Product Stability Data and Evaluation
- Storage recommendations/labelling/SmPC
- Stability studies, commitments post approval
- Typical questions from authorities and answers

Evaluation of Stability Results – Statistical Considerations

- Sample number and replication
- Trend analysis
- Outliers
- Pooling of batch data
- Shelf-life prediction



Dr Ulli Backofen Boehringer Ingelheim, Germany

Dr Backofen started his career as postdoc in pharmaceutical industry in 2001. In 2003 he became head of analytical laboratory (NCE) at Boehringer Ingelheim. From 2010 to 2018 he worked as R&D project leader and was responsible for various NCE and NBE projects. In 2018 he was appointed director and Head of Quality Control in the department Analytical Development Biologicals at Boehringer Ingelheim in Biberach.



Dr Heiko Brunner Hamburg, Germany

Dr Brunner is a chemist and has worked since 1991 for various international pharmaceutical companies in the field of product development. Since 2008 he has been with HELM AG, where he worked in the areas of pharmaceutical development, project management and analytical development and quality control. Dr Brunner was head of quality control and GMP auditor.



Dr Thomas Fürst Boehringer Ingelheim, Germany

Dr Fürst joined Schering in 1997 working in a production facility for oral dosage forms. In 2007 he joined Boehringer Ingelheim as a CMC expert. From 2013 – 2018 he was head of development of Consumer Healthcare at Boehringer (from 2017 SANOFI). Since 2018 Dr Fürst is again with Boehringer as head of laboratory of the development department.



Dr Josef Hofer EXDRA GmbH, Germany

Dr Josef Hofer is Managing Director of EXDRA GmbH (Excellence in Drug Regulatory Affairs.). Working for and in international pharmaceutical industry since 1980. Dr Hofer holds a lectureship at the University in Bonn for Drug Regulatory Affairs.



Dr Cornelia Nopitsch-Mai Formerly Quality Assessor, Germany

Dr Nopitsch-Mai was scientist at the Federal Institute for Drugs and Medical Devices in the assessment of the quality part of the dossier since 1991. Since 2000 she was assessor for the Certification Procedure (EDQM) in Strasbourg. She was member of the Technical Advisory Board (EDQM) from 2001 until 2010; in that time she was chairperson from 2005 until 2010. From 2007 until 2011 she was a member of the EMA Quality Working Party.



Dr Thomas Uhlich Bayer, Germany

Thomas Uhlich studied chemistry at Humboldt University Berlin and joined the Analytical Development function of Schering AG in 1998 after postdoctoral fellowships in the USA and Germany. Starting in 2006, he was heading a development laboratory of Bayer Pharmaceuticals. This laboratory was specialized in the development and validation of analytical methods as well as quality control and stability testing of pharmaceuticals in clinical development. Currently, he is working as a CMC Project Lead for drug development.



This Training Course is recognized for the GMP/GDP Certification Scheme

Building on your education the ECA GMP/GDP certification programmes provide you with the appropriate supplement to acquire this qualification. This training course is the first element for your additional certification. Simply choose any three courses within the programme according to your professional interest. Your certificate is then valid for two years. To renew it, you can pick any training from the ECA courses and conferences list within that two-years period – allowing you to broaden your knowledge in GMP and GDP compliance.

Please find more information at www.gmp-certification.org



Stay informed with the GMP Newsletters from ECA

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, simply scan the QR code on the right or visit www.gmp-compliance.org/gmp-newsletter



Reservation Form (Please complete in full)

specifications on the right, please fill out here: f the bill-to-address deviates from the

Stability Testing for Drug Substances and Drug Products | Live Online Training on 12/13 November 2025 Group I: APIs Manufactured by Chemical Synthesis / Drug Products Containing Chemical APIs Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes Setting Specifications and Acceptance Criteria | Live Online Training on 11/12 November 2025 Please tick ONE group for the Parallel Sessions:

☐ Group I: APIs Manufactured by Chemical Synthesis / Drug Products Containing Chemical AI ☐ Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes Purchase Order Number, if applicable Company Important: Please indicate your company's VAT ID Number CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice of to cancel an event. If the event must cancelled, registrants will be notified as soon as possible and will receive a full credit of fees paid. CONCEPT HEIDELBERG will not be Title, first name, surname E-Mail (Please fill in) Department Phone / Fax Fax +49(0) 62 21/84 44 34 CONCEPT HEIDELBERG D-69007 Heidelberg P.O. Box 101764 GERMANY

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time

via the contact form on this website.

lation or non-appearance. If you cannot take part, you have to inform us in wri-ting. The cancellation fee will then be calculated according to the point of time

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receip to payment will not be confirmed)! (As of July 2022). German law shall apply, Court of jurisdiction is Heidelberg.

responsible for discount airfare penalties or other costs incurred due to a cancellation. Terms of payment: Payable without deductions within 10 days after mportant. This is a binding registration and above fees are due in case of cancel-

receipt of invoice.

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. We are happy to welcome a substitute colleague at any time.

2. Cancellation until 4 weeks prior to the conference 10 %,

Cancellation until 2 weeks prior to the conference 25 %,

Cancellation until 2 weeks prior to the conference 50 %,

Cancellation within 2 weeks prior to the conference 50 %,

Cancellation within 2 weeks prior to the conference 50 %

Date of the Live Online Training

Wednesday, 12 November 2025, 14.00 – 17.00 h CET Thursday, 13 November 2025, 09.00 - 16.30 h CET

Technical Requirements

We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-trainingtechnical-information you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.

Conference Fees (per delegate plus VAT)

Non-ECA Members € 1,890 ECA Members € 1.690 APIC Members € 1,790 EU GMP Inspectorates € 945

The conference fee is payable in advance after receipt of invoice.



Would you like to save money?

If you book the conference "Setting Specifications" (11/12 November 2025) AND in addition the con-

ference "Stability Testing for Drug Substances and Drug Products" (12/13 November 2025) the fees reduce as follows:

Stability Testing AND Setting Specifications

ECA Members € 2,790 APIC Members € 2,890 Non-ECA Members € 2.990 EU GMP Inspectorates € 1,495

Registration

Via the attached reservation form, by e-mail or by fax - or search and register directly at www.gmp-compliance.org under the number 22028 or 22027 (for Stability Testing + Setting Specifications). To avoid incorrect information, please give us the exact address and full name of the participant.

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event: CONCEPT HEIDELBERG P.O.Box 10 17 64 | 69007 Heidelberg, Germany Phone +49(0)62 21/84 44-0 | Fax +49(0)62 21/84 44 34 info@concept-heidelberg.de | www.concept-heidelberg.de

For questions regarding content please contact: Dr Markus Funk (Director Operations) at +49 (0)62 21/84 44 40 or per e-mail at funk@concept-heidelberg.de

For questions regarding organisation etc. please contact: Ms Nicole Bach (Organisation Manager) at +49 (0)62 21/84 44 22, or per e-mail at nicole.bach@concept-heidelberg.de